EPFL spinoff QGel raises 12 million dollars from private investors

QGel is a startup that makes a synthetic gel for growing cells as if they were in the human body. This breakthrough enhances the reliability of research into anti-cancer drugs. The company has just announced that it has raised 12 million dollars from private investors, which will allow it to expand its product range. QGel was created in 2009 when co-founder and CEO Colin Sanctuary joined forces with Matthias Lütolf, a pioneer in 3D gels and a professor at EPFL. The startup is based at EPFL's Innovation Park. The company, whose products support research into anti-cancer drugs, has just received 12 million dollars in funding from private investors. QGel makes a synthetic gel - similar to the living material in which cells grow in the human body - in which cancer cells can grow into an organ as if they were in the human body.